Drug Discovery & Development | FDA Investigating Heart Failure Risk Linked To Onglyza Forbes ureThe FDA said today that it was conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin is marketed by AstraZeneca AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca ... FDA to Investigate Diabetes Drug Saxagliptin for Possible Heart Failure Risk FDA to probe saxagliptin's heart failure risk FDA Investigating Heart Failure Risks with Saxagliptin |
